News Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2026-10-02 pm EDT			5-day change	1st Jan Change
10.50 ^USD	-6.75%		-10.79%	-33.04%

Oct. 01	Monte Rosa Therapeutics Announces Positive Data From GFORCE-1 Phase 1 Study Evaluating MRT-8102	CI
Oct. 01	Monte Rosa Therapeutics, Inc. - Special Call

All News

Mentions Relevance

Oct. 02	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
Oct. 01	Monte Rosa Therapeutics Announces Positive Data From GFORCE-1 Phase 1 Study Evaluating MRT-8102	CI
Oct. 01	Monte Rosa Therapeutics, Inc. - Special Call
Oct. 01	Monte Rosa Therapeutics Says MRT-8102 Showed Biomarker Improvements in Phase 1 Study	MT
Oct. 01	Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk	GL
Oct. 01	HC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price Target	MT
Sep. 30	Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk	GL
Sep. 08	Monte Rosa Therapeutics Initiates Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader MRT-6160	CI
Sep. 08	Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)	GL
Sep. 02	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
Sep. 01	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	GL
Aug. 24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
Aug. 24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI
Aug. 24	Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	GL
Aug. 06	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 06	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, vs. FactSet Est of $12.9M	MT
Aug. 06	Monte Rosa Therapeutics: Q2 Earnings Snapshot	AQ
Aug. 06	Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates	GL
Jul. 31	Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating	MT
Jul. 02	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
Jun. 29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark	CI
Jun. 29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index	CI
Jun. 29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2000 Value Benchmark	CI
Jun. 29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Microcap Growth Benchmark Index	CI
Jun. 29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2000 Growth Benchmark	CI